BR112019010265A2 - anticorpos anti_cd137 inovadores e usos dos mesmos - Google Patents
anticorpos anti_cd137 inovadores e usos dos mesmosInfo
- Publication number
- BR112019010265A2 BR112019010265A2 BR112019010265A BR112019010265A BR112019010265A2 BR 112019010265 A2 BR112019010265 A2 BR 112019010265A2 BR 112019010265 A BR112019010265 A BR 112019010265A BR 112019010265 A BR112019010265 A BR 112019010265A BR 112019010265 A2 BR112019010265 A2 BR 112019010265A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- fragments
- human
- relates
- innovative anti
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004927 fusion Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1619648.7A GB201619648D0 (en) | 2016-11-21 | 2016-11-21 | Novel antibodies and uses thereof |
| PCT/EP2017/079930 WO2018091740A2 (en) | 2016-11-21 | 2017-11-21 | Novel antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019010265A2 true BR112019010265A2 (pt) | 2019-09-17 |
Family
ID=57993708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019010265A BR112019010265A2 (pt) | 2016-11-21 | 2017-11-21 | anticorpos anti_cd137 inovadores e usos dos mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11535678B2 (OSRAM) |
| EP (1) | EP3541844A2 (OSRAM) |
| JP (1) | JP7068303B2 (OSRAM) |
| KR (1) | KR102679632B1 (OSRAM) |
| CN (1) | CN109963873B (OSRAM) |
| AU (1) | AU2017360094B2 (OSRAM) |
| BR (1) | BR112019010265A2 (OSRAM) |
| CA (1) | CA3044339A1 (OSRAM) |
| GB (1) | GB201619648D0 (OSRAM) |
| IL (1) | IL266738B2 (OSRAM) |
| MX (1) | MX2019005911A (OSRAM) |
| NZ (1) | NZ754051A (OSRAM) |
| RU (1) | RU2019116624A (OSRAM) |
| WO (1) | WO2018091740A2 (OSRAM) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| SG11201903021WA (en) * | 2017-01-06 | 2019-05-30 | Eutilex Co Ltd | Anti-human 4-1 bb antibodies and use thereof |
| KR102629972B1 (ko) | 2017-04-13 | 2024-01-29 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| IL272349B2 (en) | 2017-08-01 | 2024-09-01 | Lilly Co Eli | ANTI-CD137 antibodies |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP7059388B2 (ja) | 2018-03-23 | 2022-04-25 | イーライ リリー アンド カンパニー | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| IL280002B2 (en) | 2018-07-12 | 2025-05-01 | F Star Beta Ltd | Antibody molecules that bind CD137 and OX40 |
| JP7598312B2 (ja) | 2018-07-23 | 2024-12-11 | ハイデルベルク ファーマ リサーチ ゲーエムベーハー | 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用 |
| MX2021001431A (es) * | 2018-08-10 | 2021-05-12 | Chugai Pharmaceutical Co Ltd | Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso. |
| CN112739718B (zh) * | 2018-09-12 | 2024-11-26 | 祐和医药科技(北京)有限公司 | 抗tnfrsf9抗体及其用途 |
| JP7558534B2 (ja) * | 2019-01-02 | 2024-10-01 | キューエルエスエフ バイオセラピューティック インコーポレイテッド | Ｃｄ１３７アゴニスト性抗体とその使用 |
| JP2022530026A (ja) | 2019-04-24 | 2022-06-27 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン抗体薬物複合体及びその使用 |
| US11725058B2 (en) * | 2019-06-26 | 2023-08-15 | Ap Biosciences, Inc. | CD137 antibodies for T-cell activation |
| KR20220087479A (ko) * | 2019-11-13 | 2022-06-24 | 허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드 | 인간 4-1bb와 결합할 수 있는 분자 및 이의 응용 |
| US11396647B2 (en) | 2020-01-07 | 2022-07-26 | Board Of Regents, The University Of Texas System | Human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| CN115066440A (zh) * | 2020-02-28 | 2022-09-16 | 上海复宏汉霖生物技术股份有限公司 | 抗cd137构建体及其用途 |
| KR20230012559A (ko) | 2020-05-19 | 2023-01-26 | 베링거 인겔하임 인터내셔날 게엠베하 | 암 치료를 위한 결합 분자 |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| EP4155319A4 (en) * | 2020-06-30 | 2024-06-12 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1BB BINDING PROTEIN AND ITS USE |
| JP7744991B2 (ja) * | 2021-01-08 | 2025-09-26 | 北京韓美薬品有限公司 | ４－１ｂｂと特異的に結合する抗体及びその抗原結合フラグメント |
| EP4355780A1 (en) | 2021-06-18 | 2024-04-24 | Alligator Bioscience AB | Novel combination therapies and uses thereof |
| GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025531938A (ja) * | 2022-09-22 | 2025-09-25 | アブリンク バイオテック カンパニー リミテッド | 抗４－１ｂｂナノボディ、その製造及び使用 |
| CN116041517B (zh) * | 2022-12-19 | 2025-02-25 | 首都医科大学附属北京胸科医院 | 一种抗人cd137抗体及其应用 |
| CN116162162B (zh) * | 2022-12-19 | 2025-05-27 | 首都医科大学附属北京胸科医院 | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 |
| CN116271009A (zh) * | 2023-01-13 | 2023-06-23 | 深圳市乐土生物医药有限公司 | 含有CpG佐剂和4-1BB抗体的药物组合物及其用途 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| JP5496669B2 (ja) | 2006-09-01 | 2014-05-21 | ジェンティセル | リンパ除去化合物、および抗原配列を含みかつプロフェッショナル抗原提示細胞をターゲットとする分子を含んでなる、特異的ｃｔｌ応答を誘発する組成物 |
| US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| US10259881B2 (en) * | 2015-02-22 | 2019-04-16 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind CD137 |
| CN107709367A (zh) * | 2015-05-21 | 2018-02-16 | 鳄鱼生物科学公司 | 新型多肽 |
-
2016
- 2016-11-21 GB GBGB1619648.7A patent/GB201619648D0/en not_active Ceased
-
2017
- 2017-11-21 KR KR1020197015905A patent/KR102679632B1/ko active Active
- 2017-11-21 NZ NZ754051A patent/NZ754051A/en unknown
- 2017-11-21 BR BR112019010265A patent/BR112019010265A2/pt unknown
- 2017-11-21 CA CA3044339A patent/CA3044339A1/en active Pending
- 2017-11-21 IL IL266738A patent/IL266738B2/en unknown
- 2017-11-21 MX MX2019005911A patent/MX2019005911A/es unknown
- 2017-11-21 CN CN201780071444.6A patent/CN109963873B/zh active Active
- 2017-11-21 JP JP2019527232A patent/JP7068303B2/ja active Active
- 2017-11-21 RU RU2019116624A patent/RU2019116624A/ru unknown
- 2017-11-21 AU AU2017360094A patent/AU2017360094B2/en active Active
- 2017-11-21 EP EP17811475.7A patent/EP3541844A2/en active Pending
- 2017-11-21 US US16/461,544 patent/US11535678B2/en active Active
- 2017-11-21 WO PCT/EP2017/079930 patent/WO2018091740A2/en not_active Ceased
-
2019
- 2019-07-17 US US16/514,374 patent/US10689454B2/en active Active
-
2022
- 2022-11-10 US US18/054,373 patent/US20230295325A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019005911A (es) | 2019-07-08 |
| US10689454B2 (en) | 2020-06-23 |
| US20190352414A1 (en) | 2019-11-21 |
| CA3044339A1 (en) | 2018-05-24 |
| AU2017360094B2 (en) | 2024-12-12 |
| CN109963873B (zh) | 2023-12-26 |
| IL266738B2 (en) | 2024-06-01 |
| CN109963873A (zh) | 2019-07-02 |
| US20230295325A1 (en) | 2023-09-21 |
| EP3541844A2 (en) | 2019-09-25 |
| NZ754051A (en) | 2023-05-26 |
| RU2019116624A (ru) | 2020-12-21 |
| KR102679632B1 (ko) | 2024-06-28 |
| WO2018091740A3 (en) | 2018-06-28 |
| IL266738B1 (en) | 2024-02-01 |
| GB201619648D0 (en) | 2017-01-04 |
| WO2018091740A2 (en) | 2018-05-24 |
| AU2017360094A1 (en) | 2019-06-20 |
| IL266738A (en) | 2019-07-31 |
| JP2020501531A (ja) | 2020-01-23 |
| RU2019116624A3 (OSRAM) | 2021-01-29 |
| JP7068303B2 (ja) | 2022-05-16 |
| US20190352411A1 (en) | 2019-11-21 |
| US11535678B2 (en) | 2022-12-27 |
| KR20190086691A (ko) | 2019-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| BR112020002012A8 (pt) | Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39 | |
| BR112018000604A2 (pt) | moléculas de anticorpo que ligam cd45 | |
| BR112022002698A2 (pt) | Compostos de imidazolil pirimidinilamina como inibidores de cdk2 | |
| BR112022006977A2 (pt) | Aminas bicíclicas como inibidores de cdk2 | |
| MX2020007898A (es) | Moduladores de cinasa de proteina asociada con rho. | |
| BR112019018685A8 (pt) | Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo | |
| BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| PH12018500233A1 (en) | Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof | |
| BR112015006060A2 (pt) | agentes de ligação kir3dl2 | |
| BR112018015419A2 (pt) | degradantes seletivos de receptor de estrogênio e os usos dos mesmos | |
| BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
| BR112017012342A2 (pt) | compostos inibitórios de bcl-xl e conjugados de anticorpo-fármaco incluindo os mesmos | |
| MX383614B (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| MX382607B (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa. | |
| BR112016028835A2 (pt) | derivados de auristatina e conjugados dos mesmos | |
| MX388660B (es) | DERIVADOS DE N-(SUSTITUIDA-FENIL)-SULFONAMIDA COMO INHIBIDORES DE QUINASA N-(sustituida-fenil)-sulfonamida. | |
| BR112017021929A2 (pt) | derivados de quinolina como inibidores tam rtk, composição farmacêutica compreendendo os referidos derivados e uso destes | |
| EA201900561A1 (ru) | Конъюгаты циклодекстрин-белок-лекарственное средство | |
| EA201890320A1 (ru) | Молекулы антител, которые связывают cd79 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |